Interviews

Research has demonstrated a reduction in hospitalization risk associated with the use of LAIs, but some barriers can prevent the wider adoption of this approach.

The ongoing "quad-demic" of influenza, norovirus, RSV, and COVID is creating heightened health risks, making prevention through hygiene, masking, and vaccination critical.

Intravenous immunoglobulin therapy for patients with CIDP requires navigating insurance coverage and prolonged therapy.

Phil Vigeant shares benefits and considerations of plant-based protein powders, highlighting the pharmacist's role in recommending quality plant-based protein powders.

According to Pranav Garimella, pharmacists are essential in counseling patients with CKD on the appropriate use of semaglutide.

Gaps in education about biosimilars, particularly among pharmacists, patients, and prescribers, are a significant barrier to wider adoption.

Etranacogene dezaparvovec offers a long-term, cost-effective solution for hemophilia B by providing sustained factor IX expression but requires careful patient selection and post-infusion liver monitoring.

Semaglutide has been approved for reducing kidney disease progression and cardiovascular risk in patients with type 2 diabetes, marking a significant advancement in CKD management.

Identifying and managing IVIG-related side effects early on in treatment can improve efficacy and safety for patients with CIDP.

Donna Ryan explains why long-term treatment with GLP-1 medication is typically necessary to maintain weight loss benefits.

Future research can explore the underlying cause of recurrent pericarditis with systemic Sjögren syndrome and the combination of rilonacept with immunosuppressive therapies.

Steven Pipe, MD, explains the long-term efficacy data surrounding etranacogene dezaparvovec in patients with hemophilia B.

Pharmacists can help educate patients, identify adverse events, and help patients communicate with other health care professionals or drug companies.

Richard Lewis discusses the critical role pharmacists and health care providers play in ensuring safe administration of IVIG for patients with CIDP.

Pharmacists should educate patients on abelacimab's potential therapeutic impact on atrial fibrillation patients at risk of stroke.

Proper nutrition and awareness of potential side effects from GLP-1 medications are essential for patients undergoing treatment.

Ming-Hei Tai, PharmD, BCOP, shares his concerns about the AQUILA trial and use of daratumumab for smoldering multiple myeloma.

Donna Ryan discusses the landscape of GLP-1 medications and the lineup of indications that the drug class has received indications for in recent years.

Christian Ruff explains the strong efficacy associated with abelacimab compared with rivaroxaban in the AZALEA-TIMI 71 trial.

Tocilizumab-anoh is expected to increase competition, improve patient access, and deliver cost savings in the treatment of various inflammatory conditions.

Three experts from UPMC Health Plan highlight the importance of treating patients’ physical, mental, and social health when managing diabetes, rather than the disease alone.

The diabetes treatment landscape is rapidly evolving, with new combination therapies and oral GLP-1 medications, positioning pharmacists to have an important role in personalizing care.

Inhaling smoke can have acute effect for people with asthma, chronic obstructive pulmonary disease (COPD), or pulmonary fibrosis.

Jennifer Clements, a clinical professor and the director of pharmacy education at the University of South Carolina, discusses the pharmacists role in diabetes care.

The California wildfires caused many medical and community challenges, including triaging services, addressing basic needs, and supporting displaced residents.

Pharmacies are actively working to address issues and support their patients by collaborative with regulatory bodies like the Board of Pharmacy, and their engagement with the local community.

Pharmacy Times interviews Jennifer Clements, a clinical professor and the director of pharmacy education at the University of South Carolina, about glucagon-like peptide-1 receptors for diabetes treatment.